

Rapid Dose Therapeutics Signs Agreement with AB Strategic Ventures for Business Development Advisory Services with First Nations Enterprises

BURLINGTON, Ontario--(BUSINESS WIRE)--November 30, 2021--Rapid Dose Therapeutics Corp. (“**RDT**” or the “**Company**”) (**CSE: DOSE**), a Canadian biotechnology company revolutionizing drug delivery through innovation, has entered into a strategic business development agreement with AB Strategic Ventures (“**ABSV**”) with the purpose of supporting relationship building with First Nations business enterprises through the fulfillment and sale of products made by Indigenous people to markets across Canada. Additionally, the agreement will support product development, branding, marketing and sales in partnership with Indigenous peoples and their respective communities to ensure cultural authenticity and appropriate positioning.

“We are pleased to partner with Indigenous peoples and businesses in building mutually beneficial relationships that will fuel their growth and nurture their economic visions,” said Mark Upsdell, CEO Rapid Dose Therapeutics. “This partnership with ABSV will assist us on our journey of understanding while appreciating the cultural values that will lead to thoughtful and meaningful collaborations all across Canada.”

ABSV works directly with Indigenous communities to promote economic and capacity development with a focus on increasing their own-source revenue streams. ABSV has raised capital, developed business and marketing plans, and has led community consultations with the private sector to custom tailor cooperation agreements that benefit all. Working with First Nations in every province and territory of Canada, ABSV has worked with more than 100 Indigenous communities throughout Canada to support the development of their economies.

“RDT has demonstrated a commitment to champion Indigenous business enterprises and we’re pleased to assist them in bringing broad-scale awareness to First Nations across Canada,” said Arnold Bomberry of AB Strategic Ventures. “Inclusivity is a much-needed approach in today’s landscape and we look forward to the opportunities that bring communities together.”

Initial product collaboration will include both RDT and private label branded products in the lifestyle, health and wellness sectors, including vitamins, nutraceuticals and topicals.

ABSV agrees to provide ongoing advisory services to RDT for an initial period of two years.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.

www.rapid-dose.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Contacts

Investors:

Mark Upsdell, CEO
mupsdell@rapid-dose.com
416-477-1052

Media:

Kim Robinson
krobinson@rapid-dose.com
905-330-4055